APOLLO BEACH, Fla. — October 16, 2025 — Leads & Copy — RetinalGenix Technologies Inc. [OTCQB: RTGN] is partnering with Seer, Inc. (Nasdaq: SEER) to identify biomarkers for earlier detection and monitoring of systemic, neurodegenerative, and retinal diseases. The collaboration integrates RetinalGenix’s retinal imaging platform with Seer Bio’s proteomic profiling to uncover disease-related molecular signatures, targeting conditions like Alzheimer’s, Parkinson’s, diabetic retinopathy, and cardiovascular diseases.
RetinalGenix has contracted Seer Bio to conduct research and clinical validation programs to accelerate diagnostic innovation. The aim is to enable broader use of early-detection solutions in clinical and home settings, potentially improving patient outcomes and reducing healthcare costs.
“Our relationship is focused on integrating ultra-high-resolution retinal imaging with advanced molecular biomarker analysis to rapidly identify and characterize disease signatures of the eye and body,” said Jerry Katzman, MD, Chairman, President, and CEO of RetinalGenix Technologies Inc.
The collaboration reflects both companies’ vision to transform early disease detection through the convergence of imaging and proteomics, ushering in personalized precision medicine and diagnostic care.
Jerry Katzman, MD, Chairman, President, and CEO of RetinalGenix Technologies Inc.
Media and Investor Relations
ir@retinalgenix.com
(800) 331-5446
Source: RetinalGenix Technologies Inc.
